Cargando…

Metabolomic Profiling in LRRK2-Related Parkinson's Disease

BACKGROUND: Mutations in LRRK2 gene represent the most common known genetic cause of Parkinson's disease (PD). METHODOLOGY/PRINCIPAL FINDINGS: We used metabolomic profiling to identify biomarkers that are associated with idiopathic and LRRK2 PD. We compared plasma metabolomic profiles of patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johansen, Krisztina K., Wang, Lei, Aasly, Jan O., White, Linda R., Matson, Wayne R., Henchcliffe, Claire, Beal, M. Flint, Bogdanov, Mikhail
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761616/ https://www.ncbi.nlm.nih.gov/pubmed/19847307 http://dx.doi.org/10.1371/journal.pone.0007551

Ejemplares similares

Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson's Disease Demonstrated by Proton Magnetic Resonance Spectroscopy
por: Aasly, Jan O., et al.
Publicado: (2015)

Exploring cancer in LRRK2 mutation carriers and idiopathic Parkinson's disease
por: Warø, Bjørg Johanne, et al.
Publicado: (2017)

What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson’s Disease Patients and Healthy Subjects with Parkinson’s-Associated LRRK2 Mutations?
por: Loeffler, David A., et al.
Publicado: (2019)

Coenzyme Q10 effects in neurodegenerative disease
por: Spindler, Meredith, et al.
Publicado: (2009)

Metabolic Profiling of CSF from People Suffering from Sporadic and LRRK2 Parkinson’s Disease: A Pilot Study
por: Yilmaz, Ali, et al.
Publicado: (2020)

Elevated LRRK2 autophosphorylation in brain-derived and peripheral exosomes in LRRK2 mutation carriers
por: Wang, Shijie, et al.
Publicado: (2017)

Inflammatory Diseases Among Norwegian LRRK2 Mutation Carriers. A 15-Years Follow-Up of a Cohort
por: Aasly, Jan O.
Publicado: (2021)

Increased Oxidative Stress Markers in Cerebrospinal Fluid from Healthy Subjects with Parkinson’s Disease-Associated LRRK2 Gene Mutations
por: Loeffler, David A., et al.
Publicado: (2017)

Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
por: Aasly, Jan O., et al.
Publicado: (2014)

A Case of Parkinson's Disease with No Lewy Body Pathology due to a Homozygous Exon Deletion in Parkin
por: Johansen, Krisztina Kunszt, et al.
Publicado: (2018)

Rasagiline in treatment of Parkinson’s disease
por: Nayak, Lakshmi, et al.
Publicado: (2008)

Ataxia with Vitamin E Deficiency in Norway
por: Elkamil, Areej, et al.
Publicado: (2015)

Inflammatory profile in LRRK2-associated prodromal and clinical PD
por: Brockmann, Kathrin, et al.
Publicado: (2016)

Models for LRRK2-Linked Parkinsonism
por: Li, Tianxia, et al.
Publicado: (2011)

The role of the LRRK2 gene in Parkinsonism
por: Li, Jie-Qiong, et al.
Publicado: (2014)

LRRK2 and Proteostasis in Parkinson’s Disease
por: Pérez-Carrión, María Dolores, et al.
Publicado: (2022)

Targeting LRRK2 in Parkinson’s disease
por: Xiao, Bin, et al.
Publicado: (2022)

Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease
por: Lai, Dongbing, et al.
Publicado: (2021)

Mitochondrial Mechanisms of LRRK2 G2019S Penetrance
por: Delcambre, Sylvie, et al.
Publicado: (2020)

Molecular insights into Parkinson's disease
por: Thomas, Bobby, et al.
Publicado: (2011)

LRRK2 contributes to monocyte dysregulation in Parkinson’s disease
por: Bliederhaeuser, Corinna, et al.
Publicado: (2016)

Writers Are Common among Parkinson's Disease Patients: A Longitudinal Study
por: Aasly, Anna, et al.
Publicado: (2021)

Mitochondrial DNA Deletions Discriminate Affected from Unaffected LRRK2 Mutation Carriers
por: Ouzren, Nassima, et al.
Publicado: (2019)

Rare variants in LRRK1 and Parkinson's disease
por: Schulte, Eva C., et al.
Publicado: (2013)

The Role of LRRK2 in Neurodegeneration of Parkinson Disease
por: Rui, Qin, et al.
Publicado: (2018)

LRRK2 and the Endolysosomal System in Parkinson’s Disease
por: Erb, Madalynn L., et al.
Publicado: (2020)

LRRK2 at the Crossroad of Aging and Parkinson’s Disease
por: Hur, Eun-Mi, et al.
Publicado: (2021)

Pathological Functions of LRRK2 in Parkinson’s Disease
por: Jeong, Ga Ram, et al.
Publicado: (2020)

Modeling Parkinson’s disease in LRRK2 rodents
por: Domenicale, Chiara, et al.
Publicado: (2023)

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study
por: Healy, Daniel G, et al.
Publicado: (2008)

Genetic and Environmental Factors Influence the Pleomorphy of LRRK2 Parkinsonism
por: Chittoor-Vinod, Vinita G., et al.
Publicado: (2021)

Long-Term Outcomes of Genetic Parkinson’s Disease
por: Aasly, Jan O.
Publicado: (2020)

Progressive Multifocal Leukoencephalopathy in an Immunocompetent Patient?
por: Johansen, Krisztina K., et al.
Publicado: (2013)

Progress in LRRK2-Associated Parkinson’s Disease Animal Models
por: Seegobin, Steven P., et al.
Publicado: (2020)

CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers
por: Majbour, Nour K., et al.
Publicado: (2020)

Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk
por: Lake, Julie, et al.
Publicado: (2021)

Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction
por: Deniston, CK, et al.
Publicado: (2020)

LRRK2 in Parkinson's disease and dementia with Lewy bodies
por: Zhu, Xiongwei, et al.
Publicado: (2006)

Genetic Variants of LRRK2 in Taiwanese Parkinson’s Disease
por: Wu, Yih-Ru, et al.
Publicado: (2013)

LRRK2 and neuroinflammation: partners in crime in Parkinson’s disease?
por: Russo, Isabella, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7mck5ssqoedjblcrasr0l91drc